Download presentation
Presentation is loading. Please wait.
1
Moderator - Prof Chandralekha Dr Jyotsna www.anaesthesia.co.inwww.anaesthesia.co.in anaesthesia.co.in@gmail.comanaesthesia.co.in@gmail.com
2
DM Hypertension Glomerulonephritis Pyelonephritis Polycystic kidney Others
3
Hemodialysis Peritoneal dialysis Transplantation
4
Diffusion of solutes across a semipermeable membrane down conc gradient Hemodialysis - shunt / fistula Peritoneal dialysis – IPD, CAPD,CCPD
5
Hyperkalemia unresponsive to conservative means Refractory acidosis Volume overload Uremic pericarditis Uremic neuropathy
6
Predominant technique Done three times a week Duration 2.5 - 5 hrs
7
Hemodialysis : Arteriovenous fistula - long term Arteriovenous shunt - short term Temporary venous catheters – short term
8
Needs 4 weeks to mature Complications : Thrombosis Infection Haemorrage Steal Precautions- Padding of fistula Avoid BP cuff No sampling Avoid hypotension
9
Peritoneum as endogenous dialysis membrane CAPD /CCPD Access via silastic catheter
10
advantagesdisadvantages Hemodialysis – short time, better small solute removal Need heparin,vascular access, hypotension, poor BP control Peritonial : steady state, higher hematocrit, better BP control, large solute removal, source of nutrition Peritonitis, hernia back pain, obesity
11
Acute : Hypovolemia Electrolyte imbalance Disequilibrium syndrome Chronic : Dialysis dementia Hypoproteinemia infections
12
Better quality of life Better 5 yr survival rates 70% vs 30% Improves anaemia, peripheral neuropathy, autonomic neuropathy and cardiomyopathy Dialysis negatively affects success of transplantation
13
Patients with ESRD with expected 5 yr survival
14
Absolute contraindications : Disseminated or untreated cancer Severe psychiatric disease Irresolvable psychosocial problems Persistent substance abuse Severe mental retardation Un-reconstructable coronary artery disease or refractory congestive heart failure
15
Treated malignancy Chronic liver disease History of substance abuse Structural genitourinary tract anomaly Past psychosocial abnormality
16
LIVE or CADAVER Live -> related or unrelated Ideal donor Age = 18 - 60yrs Compatible blood group No DM or HTN Psychologically motivated Viral markers ( - )
17
Fully informed of risk and benefits Aware of alternative methods Willing to donate Psychosocially capable Unrelated donors – Need permission from authorization committee
18
Hemogram,KFT, LFT CT angiography and urography Psychiatry, dental,opthalmologic and cardiac evaluation CMV antibodies DTPA scan and global GFR Immunological testing
19
Good physical health ASA 1or 2 Open / laparoscopic Flank position – risk of hypotension Maintain good hydration and diuresis Mannitol before cross clamping Avoid direct acting vasopressors Post op pain – iv opioids, no NSAIDS
20
Brain dead donors or non heart beating : Brain dead donors : Need peri op hemodynamic stabilization Metabolic and electrolyte disturbances Intra op goals ( rule of 100 ): Systolic BP >100 mm hg Pao2 > 100mm hg Urine output > 100ml /hr Hemoglobin > 10 gm/dl CVP between 5 -10 mm Hg
21
Muscle relaxation needed Analgesia not required Volatile and opioids needed for hemodynamic stability Non heart beating donors : Long warm ischemia time
22
CVS : ◦ Control hypertension ◦ Accelerated CAD - dyslipidemia, hypertension, Calcium & phosphate metabolism ◦ volume overload - dialysis
23
Chronic anemia Maintain hematocrit close to 25% Erythropoietin supplementation Uremic coagulopathy : deficient factor VIII, VWf and abnormal platelet function Dialysis,conjugated estrogen, desmopressin, cryoprecipitate, FFP
24
Hyperkalemia – K >5.5 need treatment Dialysis or pharmacological intervention Calcium phosphate product > 60 - calcification in vessel Hypermagnesemia - enhance muscle relaxants
25
Hypoalbuminemia or volume overload– risk of pulmonary edema Pleural effusion Dialysis, albumin supplementation
26
26 Stiff joint syndrome Autonomic neuropathy Silent MI Peripheral neuropathy Electrolyte imbalance Diffuse atherosclerosis Ensure blood sugar control
27
Risk of haemodynamic fluctuation Risk of gastric aspiration Reduced heart rate variability >15 / min is normal
28
Site of AV fistula Previous cannulation Ascites
29
ABO compatibility HLA matching Crossmatching negative PRA( panel reactive antibody) levels ideally less than10%
30
Hemoglobin, platelets,KFT,LFT, CXR,ECG, echo,MCU, viral markers,immunological testing Pre op dialysis - a day prior to surgery Patients native urine output Post dialysis inv : serum electrolytes,urea, ECG, CXR, pt weight (<2kg difference)
31
Aspiration prophylaxis – delayed gastric emptying Dose reduction of H2 antagonists Continue antihypertensives Anxiolysis - midazolam (water solubility )
32
Standard ASA monitoring -> 5 lead ECG Pulse oximeter eTCO2 Temp NIBP ( non fistula arm ) CVP ( PAC – sig LV dysfunction ) NMT
33
Thiopentone - ↑free fraction needs reduced dosing, slow rate of administration Etomidate – minimal cardiodepressant effect Ketamine - hypertensive effect ; avoid Propofol - titrated doses
34
Enflurane, methoxyflurane – flouride toxicity Desflurane, sevoflurane – safe Halothane – reduces RBF, cardiac depressant effect Isoflurane – preserves RBF, mild cardiodepressive effect, low renal toxicity Anesthetic agent of choice
35
Morphine, meperidine – metabolites renally excreted Fentanyl Sufentanil Alfentanil Remifentanil Doses reduced by 30-50%
36
Atracurium and cisatracurium - organ independent elimination Rapid sequence induction – Succinylcholine - K < 5.5 meq/L Rocuronium – 1.5mg/kg, hepatobiliary elimination Vecuronium – metabolite accumulation
37
Maintain asepsis Supine position, fistula care Preoxygenation Rapid sequence intubation – diabetics IV agents - thiopentone most popular
38
Adequate intravascular volume - improves graft function Maintain CVP – 10 -15 mm hg Mannitol - 0.5-1 g/kg Increases renal cortical blood flow and intravascular volume, free radical scavenger, increases release of prostaglandins
39
39 Low dose Dopamine has been proved neither a reduction in acute renal failure nor an improvement in renal function in patient with renal failure It also did not demonstrate improved renal protection when used in cadaveric renal transplantation. Dopexamine has been shown some renal protection during aortic surgery but its potential benefit during renal transplant has not been evaluated.
40
Furosemide - counteracts action of stress induced ADH release, inhibits Na –K ATPase to decrease O2 consumption, converts oliguric to non oliguric Calcium channel blockers – verapamil injection in renal artery.Preserves RBF, reduces effects of cold ischemia
41
Avoid potassium containing fluids in stage 5 CKD Medium / low molecular weight HES can be used Albumin can be used
42
Adequate volume status Maintain blood pressure Avoid renal vasoconstriction Prevent tubular obstruction diuretics
43
Extra caution : Intubation – avoid hypertension and tachycardia Anastomosis - avoid hypotension, hypovolemia and hyperkalemia Extubation - NMB fully reversed, awake patient
44
Monitor urine output Post op analgesia – intermittent boluses of fentanyl /morphine or PCA Potassium levels, urea and creatinine levels measure daily Maintain adequate hydration
45
TIVA – propofol with fentanyl /alfentanyl/ remifentanil /atracurium Neuraxial blocks – epidural / CSE Advantages – avoids intubation, opioids and relaxants,good post op analgesia Disadvantages : uremic coagulopathy,peripheral neuropathy,hypotension,duration of surgery
46
Local anaesthetics – Faster onset and offset Dose reduction by 25% to avoid CVS and CNS effects
47
Warm ischemia time – from clamping of donor vessels to cold perfusion and placement to anastomosis in recipient Duration affects acute tubular necrosis < 30 min Cold ischemia time : storage in preservation solution to implantation in recipient Ideally < 24 hrs upto 72 hrs
48
Mediators of ischemic injury : ATP depletion ->loss of Na K ATPase pump Movement of ions along conc gradient -> edema and cell swelling Ischemia -> anaerobic metabolism causing acidosis -> lysosomal disruption Free radical production
49
Euro Collins solution University of Wisconsin solution Bretscheider HTK solution Compositon : Rich in potassium,low Na,free radical scavengers and other ions Static or perfused storage
50
University of wisconsin soltion CollinsHTK custodial Modified HES Potassium phosphate Magnesium sulphate Adenosine Allopurinol glutathione Potassium phosphate Potassium chloride Sodium bicarbonate Glucose Magnesium sulphate Histidine Tryptophan Low potassium Ketoglutrate Calcium Magnesium mannitol
51
Local anaesthetics – Faster onset and offset Dose reduction by 25% to avoid CVS and CNS effects
52
agenteffecttoxicity steroids ↓ interleukin production Hyperglycemia myopathy osteoporosis hypertension azathioprineInhibits DNA synthesisAnaemia thrombocytopenia cyclosporineInhibits T cellsHyperkalemia hypertension nephrotoxicity hepatotocicity TacrolimusInhibits IL 2 production Nephrotoxicity hyperkalemia hypertension,seizures OKT 3Inactivates T cellCytokine release syndromne
53
Induction therapy –iv tacrolimus,MMF and methylprednisolone (2 days prior to surgery ) Maintainance therapy – same drugs on post op day 0 All three drugs continued through out life
54
1. Criteria compliance with HARRT CD4 count > 200 undetectable viral load no systemic manifestation of disease/infection
55
Thank you www.anaesthesia.co.inwww.anaesthesia.co.in anaesthesia.co.in@gmail.comanaesthesia.co.in@gmail.com
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.